Vice President
Vaxcyte
Vice President
Vaxcyte
Develops broad-spectrum vaccines for bacterial infections
The Vice President, Market Access will lead the strategy and execution of all market access activities to support the successful launch of the company’s adult pneumococcal vaccine. Reporting to the Chief Commercial Officer, this role will be accountable for ensuring broad, timely, and sustainable access across public and private channels.
As Vaxcyte prepares for its first commercial launch, the VP will operate as a hands-on leader, building foundational capabilities while directly shaping payer, provider, and policy environments. This role requires a balance of strategic leadership and execution, with a particular focus on navigating the unique access dynamics of adult vaccines, including public health recommendations, buy-and-bill reimbursement, and site-of-care considerations.
Equal Opportunity
We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
Recruitment Fraud Notice
Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent Vaxcyte in recruitment activities. Vaxcyte has an established recruitment process for all positions prior to issuing an offer for employment and we will never extend unsolicited employment offers or ask candidates to provide financial or sensitive personal information as part of the application process. All legitimate communication from Vaxcyte will come from an official @vaxcyte.com email address. Qualified and interested candidates should apply to current openings at vaxcyte.com/careers.
Vaxcyte develops vaccines to prevent bacterial infections, focusing on broad-spectrum pneumococcal vaccines and other targets like Group A Strep, periodontitis, and Shigella. Its lead product, VAX-24, covers 24 Streptococcus pneumoniae strains and is produced using the XpressCF cell-free protein synthesis platform, which enables multi-strain conjugate vaccines. The company differentiates itself by combining cell-free manufacturing with broad strain coverage and has FDA Breakthrough Therapy designation for VAX-24, helping speed development. Its goal is to bring broadly protective bacterial vaccines to market, reduce serious infections worldwide, and expand its portfolio with products like VAX-31 and additional preclinical candidates.
Explore more opportunities at Vaxcyte